A WHO-UNICEF joint statement encouraging greater health commodity supply chain integration for temperature-sensitive pharmaceuticals where appropriate, 19 November 2020
Licensed pharmaceutical products (marketing authorization) should be manufactured only by licensed manufacturers (holders of a manufacturing authorization) whose activities are regularly inspected by competent national authorities. This guide to GMP shall be used as a standard to justify GMP status,... which constitutes one of the elements of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce, through the assessment of applications for manufacturing authorizations and as a basis for the inspection of manufacturing facilities. It may also be used as training material for government medicines inspectors, as well as for production, QC and QA personnel in the industry
more
In the wake of the Covid‑19 Pandemic, parts of the public health system at increased risk of reduced efficiency include healthcare services for women and children. This in turn could reverse all the progress achieved over the years in reducing maternal and child mortality. In th...is study, an attempt has been made to assess the indirect effect of the pandemic on maternal and child health services in public health facilities.
more
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat...ed: version 15 March 2022.
more
This drill package is part of a broader COVID-19 simulation exercise package, including vaccine tabletop exercises(TTX). For exercises to be most effective, it is recommended they should be part of a comprehensive programme made up of progressively complex exercises, each exercise ... building on the previous one until they are as close to reality as possible
Available in English, Arabic, Chinese, French, Russian, Spanish and Portuguese
more
Nat Med (2021). https://doi.org/10.1038/s41591-021-01381-y
This case study takes a closer look at experiences in three countries and one sub-region, each with a unique profile, a specific set of challenges and opportunities, and differing levels of WASH competencies. Through the lens of the participating National Societies and the communities they serve, th...is study captures rich layers of learning from multi-country implementation between 2016 to 2020.
The unfolding of the COVID-19 pandemic gives a glimpse of the resulting global restrictions that are testing aspects of National Society capacity and preparedness on the ground. It is an opportunity to take stock of progress and the outlook ahead - to celebrate achievements and share experiences with National Societies and partners contemplating capacity development in emergency WASH in the Asia Pacific region.
more
The right to adequate housing, despite having been recognized by multiple international instruments, continues to be a human right that is consistently violated. Around 2O% of the world's population do not have adequate housing . In Latin America, informal settlements generally lack the conditions r...equired to live a decent life, and local and national public policies fail to radically transform this situation.
more
This mapping of community experiences for the defense of the right to adequate housing in situations of risk of eviction or eviction in progress brings together practices and strategies used by families, collectives and community organizations that have different origins and interests in the region,... and also those on other continents.
more
Background paper 10
The Independent Panel for Pandemic Preparedness and Response
May 2021
9 June 2021
Since its launch, GLASS has expanded in scope and coverage and as of May 2021, 109 countries and territories worldwide have enrolled in GLASS. A key new component in GLASS is the inclusion of antimicrobial consumption (AMC) surveillance at the national level highlighted in this fourth G...LASS report.
The fourth GLASS report summarizes the 2019 data reported to WHO in 2020. It includes data on AMC surveillance from 15 countries and AMR data on 3 106 602 laboratory-confirmed infections reported by 24 803 surveillance sites in 70 countries, compared to the 507 923 infections and 729 surveillance sites reporting to the first data call in 2017.
The report also describes developments over the past years of GLASS and other AMR surveillance programmes led by WHO, including resistance to anti-human immunodeficiency virus and anti-tuberculosis medicines, antimalarial drug efficacy.
more
This brief summarizes current evidence and guidance for maintaining safe and effective care across the spectrum of maternal, newborn and infant care while protecting mother and child and health care providers during COVID-19. Furthermore, implications of the principle of “do no harm” are reviewe...d for maternal, newborn and infant care delivery during COVID-19, so that this information is conveniently and readily available to clinical and health system policy leaders and stakeholders in countries and communities. Additionally, considerations for safe oxygen delivery as well as key Infection Prevention and Control (IPC) measures at home and in healthcare facilities for pregnant women, newborns and children are described in detail in the brief.
more
Modelling the health impacts of disruptions to essential health services during COVID-19 Module 1
Several epidemiological models have been created to assess the potential impact of disruptions to essential health services caused by COVID-19 on morbidity and mortality from conditions other than COVI...D-19 illness. This guide presents models that have been used to assess these indirect impacts. The effects have been studied in various settings, using a variety of models.
The guide is intended for people who need to understand what the models say, their construction and their underlying assumptions, or need to use models and their outcomes for planning and programme development and to support policy decisions for a country or region.
more
Pharmaceutical regulators are at the forefront of ensuring that only safe and effective medicines are authorized and available in the market. This document builds on the recommendations in the above publication and has been prepared to specifically assist national medicines regulatory authorities to... understand the nature and extent of oxytocin quality issues and to provide key technical information and quality requirements for oxytocin products in dossier assessments. Furthermore, this document also presents recommendations on other regulatory actions needed to ensure that only quality-assured oxytocin products are authorized and made available to women.
more